Impact of high-throughput screening in biomedical research
The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
High-throughput screening (HTS) has been postulated in several quarters to be a contributory factor to the decline in productivity in the pharmaceutical industry. Moreover, it has been blamed for stifling the creativity that drug discovery demands. In this article, we aim to dispel these myths and present the case for the use of HTS as part of a proven scientific tool kit, the wider use of which is essential for the discovery of new chemotypes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cell-based phenotypic screening of chemical libraries represents a powerful tool to identify new potential drugs48.”
From Identification and characterization of Cardiac Glycosides as senolytic compounds (2019) · cites this paper as [48]
Citations
Cites
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847 · cited 1×
“HTS laboratories have pioneered and implemented rigorous quality assurance methods, such as Z′ trend monitoring”
MethodCan the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 1×
“These efforts typically take 2–3 years in most drug discovery companie”
BackgroundDrug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237 · cited 1×
“There have been numerous analyses of pharmaceutical industry productivity, and several of these have blamed high-throughput screening (HTS) as a factor undermining the creativity that has sustained the industry over the past centur”
BackgroundDiscovery and development of sorafenib: a multikinase inhibitor for treating cancer
Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., Schwartz, B., Simantov, R., & Kelley, S. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2130 · Cited by 1,829
Lessons from 60 years of pharmaceutical innovation
Munos, B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2961 · Cited by 1,207
Dorr, P., Westby, M., Dobbs, S., Griffin, P., Irvine, B., Macartney, M., Mori, J., Rickett, G., Smith-Burchnell, C., Napier, C., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4721-4732.2005 · Cited by 1,152
Hit and lead generation: beyond high-throughput screening
Bleicher, K. H., Böhm, H.-J., Müller, K., & Alanine, A. I. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1086 · Cited by 1,056
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
Gao, M., Nettles, R. E., Belema, M., Snyder, L. B., Nguyen, V. N., Fridell, R. A., Serrano-Wu, M. H., Langley, D. R., Sun, J.-H., O’Boyle II, D. R., et al. (2010) · Nature · doi:10.1038/nature08960 · Cited by 939 · cited 1×
“This approach was used to discover compounds that inhibited hepatitis C virus replication and, after consequent optimization, the approach yielded efficacious clinical candidates with a broad genotype coverag”
MethodA Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase
Fry, D. W., Kraker, A. J., McMichael, A., Ambroso, L. A., Nelson, J. M., Leopold, W. R., Connors, R. W., & Bridges, A. J. (1994) · Science · doi:10.1126/science.8066447 · Cited by 806
Do Structurally Similar Molecules Have Similar Biological Activity?
Martin, Y. C., Kofron, J. L., & Traphagen, L. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020155c · Cited by 806 · cited 1×
“There are many methods that can be used to define the chemotype and diversity of compounds, with some validated by years of screening dat”
MethodIs There a Difference between Leads and Drugs? A Historical Perspective
Oprea, T. I., Davis, A. M., Teague, S. J., & Leeson, P. D. (2001) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci010366a · Cited by 769 · cited 1×
“A strong emphasis on the physicochemical properties of compounds — using concepts such as drug-like properties and lead-like properties”
BackgroundThe influence of lead discovery strategies on the properties of drug candidates
Keserü, G. M., & Makara, G. M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2796 · Cited by 628
Pursuing the leadlikeness concept in pharmaceutical research
Hann, M. M., & Oprea, T. I. (2004) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2004.04.003 · Cited by 515 · cited 1×
“A strong emphasis on the physicochemical properties of compounds — using concepts such as drug-like properties and lead-like properties”
BackgroundFink, T., & Reymond, J.-L. (2007) · Journal of Chemical Information and Modeling · doi:10.1021/ci600423u · Cited by 457 · cited 1×
“This raises a question: why stop at 1 million, 2 million or 3 million compounds? Given the size of the 'drug like' chemical space (estimated at >1 × 10 30 compounds”
BackgroundDas, J., Chen, P., Norris, D., Padmanabha, R., Lin, J., Moquin, R. V., Shen, Z., Cook, L. S., Doweyko, A. M., Pitt, S., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060727j · Cited by 397
Frye, S. V. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.296 · Cited by 375 · cited 1×
“Visionary academics believe that small-molecule probes discovered by combining HTS and new biology will ultimately lead to the development of a fundamental understanding of disease pathologies and human healt”
BackgroundOPC-21268, an Orally Effective, Nonpeptide Vasopressin V1 Receptor Antagonist
Yamamura, Y., Ogawa, H., Chihara, T., Kondo, K., Onogawa, T., Nakamura, S., Mori, T., Tominaga, M., & Yabuuchi, Y. (1991) · Science · doi:10.1126/science.1850553 · Cited by 271
Rebuilding the R&D engine in big pharma.
Garnier, J.-P. (2008) · PubMed · Cited by 228
High-Throughput Screening: Update on Practices and Success
Fox, S., Farr-Jones, S., Sopchak, L., Boggs, A., Nicely, H. W., Khoury, R., & Biros, M. (2006) · SLAS Discovery · doi:10.1177/1087057106292473 · Cited by 217
Cuatrecasas, P. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29999 · Cited by 209 · cited 1×
“The need for a project champion has been highlighted by others as a key element in many successful drug discovery programme”
BackgroundDiscovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist
Erickson-Miller, C. L., DeLorme, E., Tian, S.-S., Hopson, C. B., Stark, K., Giampa, L., Valoret, E. I., Duffy, K. J., Luengo, J. L., Rosen, J., et al. (2005) · Experimental Hematology · doi:10.1016/j.exphem.2004.09.006 · Cited by 207 · cited 1×
“Although the initial hits had poor physicochemical properties, medicinal chemists were able to optimize the properties and ultimately produce a marketed dru”
BackgroundThornberry, N., & Weber, A. (2007) · Current Topics in Medicinal Chemistry · doi:10.2174/156802607780091028 · Cited by 202
Identification of Hepatitis C Virus NS5A Inhibitors
Lemm, J. A., O'Boyle, D., Liu, M., Nower, P. T., Colonno, R., Deshpande, M. S., Snyder, L. B., Martin, S. W., St. Laurent, D. R., Serrano-Wu, M. H., et al. (2010) · Journal of Virology · doi:10.1128/jvi.01360-09 · Cited by 194 · cited 1×
“This approach was used to discover compounds that inhibited hepatitis C virus replication and, after consequent optimization, the approach yielded efficacious clinical candidates with a broad genotype coverag”
MethodPerola, E. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100118x · Cited by 188 · cited 1×
“Even with all these caveats, in a recent analysis of 58 drugs (for which the starting lead was known) that were approved between 1991 and 2008 (Ref”
BackgroundCellular assays as portals to seven-transmembrane receptor-based drug discovery
Kenakin, T. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2838 · Cited by 159
Thaisrivongs, S., Tomich, P. K., Watenpaugh, K. D., Chong, K.-T., Howe, W. J., Yang, C.-P., Strohbach, J. W., Turner, S. R., & McGrath, J. P. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00046a002 · Cited by 150
Drewry, D., & Macarron, R. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.03.024 · Cited by 124 · cited 1×
“Many targets being pursued today (for example, novel enzymes and protein–protein interactions) may require compounds that are different from those in compound collections of the past, and most companies reserve some investment for atypical chemotypes; for example, natural product mimic”
BackgroundRiechers, H., Albrecht, H.-P., Amberg, W., Baumann, E. A., Bernard, H., Böhm, H., Klinge, D., Kling, A., Müller, S., Raschack, M., et al. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm960274q · Cited by 121
Duffy, K. J., Darcy, M. G., Delorme, E., Dillon, S. B., Eppley, D. F., Erickson‐Miller, C. L., Giampa, L., Hopson, C. B., Huang, Y., Keenan, R. M., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010283l · Cited by 121 · cited 1×
“A cell-based luciferase reporter screen for thrombopoietin receptor (TPOR) agonists was performed against ∼260,000 compound”
MethodThaisrivongs, S., Watenpaugh, K. D., Howe, W. J., Tomich, P. K., Dolak, L. A., Chong, K.-T., Tomich, C.-S. C., Tomasselli, A. G., & Turner, S. R. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00018a023 · Cited by 120
Fluorescence techniques: shedding light on ligand–receptor interactions
Hovius, R., Vallotton, P., Wohland, T., & Vogel, H. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01503-0 · Cited by 102
Corte, B. L. D. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm040127p · Cited by 99
Makarenkov, V., Zentilli, P., Kevorkov, D., Gagarin, A., Malo, N., & Nadon, R. (2007) · Bioinformatics · doi:10.1093/bioinformatics/btm145 · Cited by 97
Duffy, K. J., Shaw, A. N., Delorme, E., Dillon, S. B., Erickson‐Miller, C. L., Giampa, L., Huang, Y., Keenan, R. M., Lamb, P., Liu, N., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm025535c · Cited by 88 · cited 1×
“Although the initial hits had poor physicochemical properties, medicinal chemists were able to optimize the properties and ultimately produce a marketed dru”
BackgroundCurrent In Vitro Kinase Assay Technologies: The Quest for a Universal Format
Jia, Y., Quinn, C. T., Kwak, S., & Talanian, R. V. (2008) · Current Drug Discovery Technologies · doi:10.2174/157016308783769414 · Cited by 85
(Research Papers) Design of a Compound Screening Collection for use in High Throughput Screening
Harper, G., Pickett, S. T. A., & Green, D. V. S. (2004) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/138620704772884832 · Cited by 77
Self-citationJacoby, E., Schuffenhauer, A., Popov, M., Azzaoui, K., Havill, B., Schopfer, U., Engeloch, C., Staněk, J., Acklin, P., Rigollier, P., et al. (2005) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026053828376 · Cited by 76 · cited 1×
“, and large investments in analytical quality control — led to the removal of as much as 40–50% of compounds in some of the librarie”
BackgroundSelf-citationMalignant glioma drug discovery – targeting protein kinases
Sathornsumetee, S., Vredenburgh, K. A., Lattimore, K. P., & Rich, J. N. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.1.1 · Cited by 65
Exploiting Chemical Diversity for Drug Discovery
(2006) · Royal Society of Chemistry eBooks · doi:10.1039/9781847552556 · Cited by 65
Driving Drug Discovery: The Fundamental Role of Academic Labs
Silber, B. M. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000169 · Cited by 60
Duffy, K. J., Price, A. T., Delorme, E., Dillon, S. B., Duquenne, C., Erickson‐Miller, C. L., Giampa, L., Huang, Y., Keenan, R. M., Lamb, P., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm0255365 · Cited by 59 · cited 1×
“Although the initial hits had poor physicochemical properties, medicinal chemists were able to optimize the properties and ultimately produce a marketed dru”
BackgroundA Standard Operating Procedure for Assessing Liquid Handler Performance in High-Throughput Screening
Taylor, P. B., Ashman, S. M., Baddeley, S. M., Bartram, S. L., Battle, C. D., Bond, B. C., Clements, Y. M., Gaul, N. J., McAllister, W. E., Mostacero, J. A., et al. (2002) · SLAS DISCOVERY · doi:10.1177/1087057102238630 · Cited by 58 · cited 1×
“, and liquid handler and reader performance monitorin”
BackgroundSelf-citationProcess Validation and Screen Reproducibility in High-Throughput Screening
Coma, I., Clark, L., Díez, E., Harper, G., Herránz, J., Hofmann, G. A., Lennon, M. G., Richmond, N. J., Valmaseda, M., & Macarrón, R. (2009) · SLAS DISCOVERY · doi:10.1177/1087057108326664 · Cited by 50
Case study: impact of technology investment on lead discovery at Bristol–Myers Squibb, 1998–2006
Houston, J. G., Banks, M. N., Binnie, A., Brenner, S. L., O’Connell, J., & Petrillo, E. W. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.11.004 · Cited by 49 · cited 1×
“Critically, this drive for cost-effectiveness, parallel data generation and low-volume assays by leveraging HTS technology has encouraged engineers and scientists to refine process flows and reduce timeline”
BackgroundSelf-citationCryopreserved cells facilitate cell-based drug discovery
Zaman, G. J. R., de Roos, J. A. D. M., Blomenröhr, M., van Koppen, C. J., & Oosterom, J. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.05.008 · Cited by 48
The year's new drugs & biologics - 2009
Graul, A. I., Sorbera, L. A., Pina, P., Tell, M., Cruces, E., Rosa, E., Stringer, M., Castaner, R. M., & Revel, L. (2010) · Drug News & Perspectives · doi:10.1358/dnp.2010.23.1.1440373 · Cited by 48
Defining and maintaining a high quality screening collection: the GSK experience
Lane, S. J., Eggleston, D. S., Brinded, K. A., Hollerton, J. C., Taylor, N., & Readshaw, S. A. (2006) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03730-x · Cited by 47 · cited 1×
“, and large investments in analytical quality control — led to the removal of as much as 40–50% of compounds in some of the librarie”
BackgroundLeifert, W. R., Aloia, A. L., Bucco, O., Glatz, R., & McMurchie, E. J. (2005) · SLAS DISCOVERY · doi:10.1177/1087057105280517 · Cited by 38
Evolution of cell-based reagent provision
Cawkill, D., & Eaglestone, S. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.08.014 · Cited by 36
The completed human genome: implications for chemical biology
Austin, C. P. (2003) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(03)00083-8 · Cited by 35
Application of Division Arrest Technology to Cell-Based HTS: Comparison with Frozen and Fresh Cells
Kunapuli, P., Zheng, W., Weber, M., Solly, K. J., Mull, R., Platchek, M., Cong, M., Zhong, Z., & Strulovici, B. (2005) · Assay and Drug Development Technologies · doi:10.1089/adt.2005.3.17 · Cited by 33
Functional Cell-Based Assays in Microliter Volumes for Ultra-High Throughput Screening
Wunder, F., Kalthof, B., Müller, T. J. J., & Hüser, J. (2008) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/138620708785204054 · Cited by 29
LaMattina, J. L. (2008) · Wiley eBooks · doi:10.1002/9780470434673 · Cited by 28
Mullin, R. (2004) · Chemical & Engineering News · doi:10.1021/cen-v082n030.p023 · Cited by 28
Mullin, R. (2004) · Chemical & Engineering News · doi:10.1021/cen-v082n007.p023 · Cited by 28
Evaluation of Division-Arrested Cells for Cell-Based High-Throughput Screening and Profiling
Digan, M. E., Pou, C., Niu, H., & Zhang, J.-H. (2005) · SLAS DISCOVERY · doi:10.1177/1087057105276474 · Cited by 24
Industrial-Style Screening Meets Academic Biology
Kaiser, J. (2008) · Science · doi:10.1126/science.321.5890.764 · Cited by 24
Confocal Fluorescence Microscopy for High-Throughput Screening of G-Protein Coupled Receptors
Heilker, R., Zemanová, L., Valler, M. J., & Nienhaus, G. U. (2005) · Current Medicinal Chemistry · doi:10.2174/092986705774370637 · Cited by 23
Drug Truths: Dispelling the Myths About Pharma R & D
LaMattina, J. L. (2008) · Cited by 23
The A, B, Cs of G-protein-coupled receptor pharmacology in assay development for HTS
McLoughlin, D. J., Bertelli, F., & Williams, C. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.5.603 · Cited by 21 · cited 1×
“Of particular note in this respect is the enablement of whole-cell screening, which may better reflect the pharmacology of the target or indeed facilitate screening of holistic mechanisms and pathways, rather than isolated target approache”
BackgroundG-Protein Coupled Receptor Assays: To Measure Affinity or Efficacy that is the Question
Williams, C., & Sewing, A. (2005) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207054020778 · Cited by 19 · cited 1×
“Of particular note in this respect is the enablement of whole-cell screening, which may better reflect the pharmacology of the target or indeed facilitate screening of holistic mechanisms and pathways, rather than isolated target approache”
BackgroundHigh-Content Analysis of Kinase Activity in Cells
Gasparri, F., Sola, F., Bandiera, T., Moll, J. K., & Galvani, A. P. (2008) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/138620708785204126 · Cited by 19 · cited 1×
“Of particular note in this respect is the enablement of whole-cell screening, which may better reflect the pharmacology of the target or indeed facilitate screening of holistic mechanisms and pathways, rather than isolated target approache”
BackgroundLahana, R. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02734-x · Cited by 11 · cited 1×
“There have been numerous analyses of pharmaceutical industry productivity, and several of these have blamed high-throughput screening (HTS) as a factor undermining the creativity that has sustained the industry over the past centur”
BackgroundOvercoming the obstacles in the pharma/biotech industry: 2009 update
Graul, A. I., Revel, L., Tell, M., Rosa, E., & Cruces, E. (2010) · Drug News & Perspectives · doi:10.1358/dnp.2010.23.1.1437302 · Cited by 5
Research works printed but not linked: 5
- Landers, P. Human Element: drug industry's big push into technology falls short — testing machines were built to streamline research — but may be stifling it — officials see payoff after 2010. The Wall Street Journal 1 (24 Feb 2004).
- Mullin, R. As high-throughput screening draws fire, researchers leverage science to put automation into perspective. Chem. Eng. News 82, 23–32 (2004).
- HTStec Limited. Cellular Assay Reagents Trends 2009 Report (Cambridge, UK, 2009).
- LaMattina, J. L. (ed.) in Drug Truths: Dispelling the Myths About Pharma R&D 65–66 (John Wiley and Sons, Inc., Hoboken, New Jersey, 2009).
- Inglese, J. in Ask the Expert Forum, ACS Chemical Biology. ACS Publications [online] http://community.acs.org/ChemBiol/AsktheExpert/AsktheExpertArchive/tabid/67/Default.aspx (2008).
Cited by
Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death
Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., Patel, D. N., Bauer, A. J., Cantley, A. M., Yang, W. S., et al. (2012) · Cell · doi:10.1016/j.cell.2012.03.042 · Cited by 18,691
“To overcome the inherent limitations of many individual small-molecule collections (Macarron et al., 2011), we assembled a custom screening library of 9,517 small molecules derived from a starting pool of 3,372,615 commercially available compounds that were filtered in silico on the basis of drug…”
MethodNatural products as sources of new drugs from 1981 to 2014
Newman, D. J., & Cragg, G. M. (2016) · Journal of Natural Products · doi:10.1021/acs.jnatprod.5b01055 · Cited by 5,858
Natural products as sources of new drugs over the 30 years from 1981 to 2010
Newman, D. J., & Cragg, G. M. (2012) · Journal of Natural Products · doi:10.1021/np200906s · Cited by 4,687
Natural products: A continuing source of novel drug leads
Cragg, G. M., & Newman, D. J. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.02.008 · Cited by 2,906
“, (also from GSK) when looking at different disease targets [247].”
BackgroundThe re-emergence of natural products for drug discovery in the genomics era
Harvey, A. L., Edrada-Ebel, R., & Quinn, R. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4510 · Cited by 2,572
Metadata
- Authors
- Macarron, R., Banks, M. N., Bojanic, D., Burns, D. J., Cirovic, D. A., Garyantes, T., Green, D. V. S., Hertzberg, R. P., Janzen, W. P., Paslay, J. W., Schopfer, U., & Sittampalam, G. S.
- Affiliations
- Bristol-Myers Squibb (United States) (US)
- Novartis (United States) (US)
- Abbott (United States) (US)
- Sanofi (France) (FR)
- GlaxoSmithKline (United Kingdom) (GB)
- GlaxoSmithKline (United States) (US)
- University of North Carolina at Chapel Hill (US)
- The University of Kansas Cancer Center (US)
- Novartis (Switzerland) (CH)
- Pfizer (United States) (US)
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-03
- Volume
- 10
- Issue
- 3
- Pages
- 188-195
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2031441006
- Cited by
- 1,364
- References
- 65
- Citations by year
- 2026: 113 · 2025: 117 · 2024: 99 · 2023: 103 · 2022: 82 · 2021: 107 · 2020: 106 · 2019: 77 · 2018: 105 · 2017: 87 · 2016: 96 · 2015: 64 · 2014: 61 · 2013: 73 · 2012: 54
- FWCI
- 6.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- high-throughput screening, drug discovery, chemical biology
- MeSH terms
- Animals, Drug Evaluation, Preclinical, Humans, Drug Design, Biomedical Research, Small Molecule Libraries
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.